Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 22;14:5131–5144. doi: 10.2147/OTT.S322852

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Luo et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Effects of 18β-Gly on MAPK/STAT3/NF-κB signaling pathways in A549 cells. (A) Expression levels of p-p38, p-JNK, p-ERK, p-STAT3, NF-κB, and IκB-α were measured by Western blotting. (B) Expression levels of STAT3, NF-κB, and p-IκB in the nucleus were measured by Western blotting. (C) Expression levels of p-p38, p-STAT3, Bcl-2, cle-cas-3, and cle-PARP proteins in 18β-Gly and p38 inhibitor-treated A549 cells. (D) Expression levels of p-JNK, p-STAT3, Bcl-2, cle-cas-3, and cle-PARP proteins in 18β-Gly and JNK inhibitor-treated A549 cells. (E) Expression levels of p-ERK, p-STAT3, Bcl-2, cle-cas-3, and cle-PARP proteins in 18β-Gly- and ERK inhibitor-treated A549 cells. β-actin and Lamin B1 were served as the loading controls. *P < 0.05, **P < 0.01, ***P < 0.001 vs 0 h or 18β-Gly + MAPK inhibition.